WO1998040083A1 - Medicinal preparation containing a lipophilic inert gas - Google Patents
Medicinal preparation containing a lipophilic inert gas Download PDFInfo
- Publication number
- WO1998040083A1 WO1998040083A1 PCT/EP1998/001304 EP9801304W WO9840083A1 WO 1998040083 A1 WO1998040083 A1 WO 1998040083A1 EP 9801304 W EP9801304 W EP 9801304W WO 9840083 A1 WO9840083 A1 WO 9840083A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- xenon
- anaesthesia
- emulsion
- inert gas
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
- A61M16/0841—Joints or connectors for sampling
- A61M16/085—Gas sampling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
- A61M2230/43—Composition of exhalation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
- A61M2230/43—Composition of exhalation
- A61M2230/437—Composition of exhalation the anaesthetic agent concentration
Definitions
- a further object of the present invention is to provide a liquid preparation for inflammation therapy.
- Another object of the present invention is the provision of an infusion agent for inducing or maintaining anaesthesia which overcomes all or some of the draw backs of the above described prior art.
- Still another object of the invention relates to methods of treatment wherein a preparation will be parenterally administered to induce anaesthesia, sedation, analgesia and/or muscle relaxation.
- a preparation will be parenterally administered to induce anaesthesia, sedation, analgesia and/or muscle relaxation.
- the present invention contemplates to utilize gases as such or mixtures thereof, such as xenon and/or krypton.
- Blood substitutes especially perfluorocarbon emulsions (e.g. Perflubron) , can be regarded as examples of such liquids.
- perfluorocarbon emulsions e.g. Perflubron
- Perfluorocarbons can be administered intrapulmo- narily, inter alia, so when they are loaded with xenon they can also be used on the one hand to treat acute lung damage, but on the other hand also to induce anaesthesia, sedation and/or analgesia on the basis of the pharmacological action of xenon.
- the intrapulmo- nary administration of perfluorocarbon together with xenon for partial liquid ventilation and additionally for anaesthesia or else alleviation of pain is a novel approach to the treatment of severe respiratory crises. It reopens collapsed, atelectatic areas of the lung which cannot be reached by conventional therapy, thereby preparing these areas of the lung for renewed gas exchange.
- monobrominated perfluorocarbons for example 1-bromoheptadecafluorooctane (CaFi ⁇ Br) , 1- bromopentadecafluoroheptane (C 7 F 15 Br) and 1-bromotri- decafluorohexane .
- Other compounds can also be used, including perfluoroalkylated ethers or poly- ethers, e.g.
- the volume of the gas to be included in the liquid preparation of the present invention may be measured by simple methods known to the skilled person, such as gravimetric measurements or other analytical means, or control measurements with for instance radioactive xenon (i.e. Xenon 133) as described by Gerald L. Pollack (see above) .
- the invention also provides (fatty) emulsions containing the lipophilic inert gas dissolved or dispersed in the lipid phase.
- xenon can be added to an (fatty) emulsion in appreciable amounts.
- xenon can be dissolved or dispersed in concentrations of 0.2 to 10 ml or more per ml of emulsion (concentrations relate to standard conditions, i.e. 20°C and normal pressure).
- concentrations relate to standard conditions, i.e. 20°C and normal pressure.
- the xenon concentration depends on a large number of factors, especially the concentration of the fat or lipophilic substance.
- the preparations according to the invention will be "loaded” with xenon up to the saturation limit.
- very small concentrations to be present, provided, for example, that a pharmacological activity can still be observed on intravenous administration.
- solubility of the inert gas in the emulsions can be increased by using so-called solubility promotors such as smaller lipophilic compounds which may or may not have a pharmaceutical effect (molecular weight of about 30 to about 1000; n-octanol/water partition coefficient preferably greater than 500) . It has been found that aromatic compounds such as 2,6- dialkylphenols (e.g. 2 , 6-diisopropylphenol) significantly improve the loading capacity of emulsions for inert gases.
- solubility promotors such as smaller lipophilic compounds which may or may not have a pharmaceutical effect (molecular weight of about 30 to about 1000; n-octanol/water partition coefficient preferably greater than 500) .
- aromatic compounds such as 2,6- dialkylphenols (e.g. 2 , 6-diisopropylphenol) significantly improve the loading capacity of emulsions for inert gases.
- contrast media containing a gas especially for ultrasound studies or nuclear magnetic resonance spectrometry .
- An essential feature of such contrast media is that a separate phase is formed which is made up of very small gas bubbles (or even gas- filled balloons) (cf. inter alia WO-A-96/39197 , US-A- 5 088 499, US-A-5 334 381, WO-A-96/41647 ) .
- gases including especially air, nitrogen, carbon dioxide, oxygen and also inert gases in general (i.e. helium, argon, xenon and neon).
- EP-B-0 357 163 discloses in definite terms that xenon- containing media in particular can be used as X-ray contrast media.
- the injectable solution must contain gas bubbles.
- WO-A-95/27438 discloses the use of xenon in a method of imaging of a noble gas by nuclear magnetic resonance.
- xenon has an analgesic or anaesthetic action when used as a contrast medium or for spectrometry. In fact, such an action would also be undesirable.
- the gas concentration in contrast media is also so small that the limiting concentration for a pharmacological action is not reached. Therefore, contrast media as such or formulations to be used in spectrometry are not claimed in the present patent application.
- the lipid phase of the preparation which takes up the gas, i.e. which can dissolve and/or disperse the gas, is formed mainly of so-called fats, said fats being essentially esters of long-chain and medium-chain fatty acids.
- Such fatty acids saturated or unsatu- rated, contain 8 to 20 carbon atoms.
- omega-3 or omega-6 fatty acids which can contain up to 30 carbon atoms.
- Suitable esterified fatty acids are especially plant oils, e.g. cottonseed oil, soya bean oil and thistle oil, fish oil and the like.
- the major constituent of these naturally occurring oils are fatty acid triglycerides.
- Preparations in the form of so-called oil-in-water emulsions are of particular importance, the proportion of fat in the emulsion conventionally being 5 to 30% by weight, preferably 10 to 20% by weight.
- an emulsifier is present together with the fat, proven emulsifiers being soya phosphatides, gelatin or egg phosphatide.
- Such emulsions can be prepared by emulsifying the water-immiscible oil with water in the presence of the emulsifier, which is normally a surface-active agent.
- polar solvents can also be present with the water, examples being ethanol and glycerol (propylene glycol, hexylene glycol, polyethylene glycol, glycol monoethers, a water-miscible ester, etc.).
- the inert gas can already have been incorporated into the lipid phase in a previous process step. In the simplest case, however, the preprepared emulsion is loaded with the xenon. This can take place at various temperatures, for example at temperatures from 1°C to room temperature. It is occasionally useful here to apply a pressure, for example of up to 8 atmospheres or more, to the vessel containing the emulsion.
- fatty emulsions such as those employed in intravenous feeding.
- These fatty emulsions consist essentially of a suitable fatty base (soya bean oil or sunflower seed oil) and a well-tolerated emulsifier (phosphatides) .
- Fatty emulsions in general use are Intralipid ® ,
- the fatty emulsions generally also contain additives which make the osmolarity of the aqueous phase, surrounding the fatty phase present in the form- of liposomes, isotonic with the blood. Glycerol and/or xylitol can be used for this purpose. Furthermore, it is frequently useful to add an antioxidant to the fatty emulsion in order to prevent oxidation of the unsatu- rated fatty acids. Vitamin E (DL-tocopherol) , in particular, is suitable for this purpose.
- US-A-5 334 381 illustrates in detail how liposomes can be loaded with gas.
- a device is filled with the liposomes, i.e. with an oil- in-water emulsion, and the device is then pressurized with the gas inside.
- the temperature can be reduced to as low as 1°C in this process.
- the gas gradually dissolves under pressure and passes into the liposomes.
- the lipids which form the liposomes can be of natural or synthetic origin. Examples of such materials are cholesterol, phosphatidylcholine, phos- phatidylethanolamine, phosphatidylserine, phosphatidyl- glycerol, phosphatidylinositol, sphingomyelin, glyco- sphingolipids, glucolipids, glycolipids, etc.
- the surface of the liposomes can moreover be modified by a polymer, for example by polyethylene glycol.
- the preparations according to the invention thus have a large number of advantages .
- a virtually immediate anaesthetic effect took place which, in contrast to all known injectable anaesthetics, could easily be controlled.
- the agent according to the invention has not only an anaesthetic action but also a simultaneous analgesic action and, on waking, a euphoretic action.
- the elimination from the body depends exclusively on the respiration.
- an intravenous anaesthetic the xenon concentration can easily be measured in the exhaled air. The control of anaesthesia which can be achieved in this way was not possible hitherto with conventional intravenous anaesthetics.
- the invention thus provides medicinal liquid preparations containing a lipophilic inert gas in a pharmacologically effective concentration with the proviso that preparations used as contrast media or for spectrometry are excluded.
- Pharmacologically effective is understood here as meaning anaesthetic (including subanaesthetic) , analgesic, muscle relaxing, sedative and/or anti-inflammatory.
- the pharmacological effectiveness of the present invention may relate to the systemic action on the central nervous system.
- the xenon load in the medicinal preparation may be about 0.2 to 0.3 ml of xenon per ml of emulsion.
- An anti-inflammatory action may be already observed at 0.1 ml/ml emulsion. It was observed that, with continuous infusion over 30 sec, 20 ml of an emulsion containing 0.3 ml of Xe per ml of emulsion produce a subanaesthetic condition in a patient weighing about 85 kg.
- the above given concentration limits may be operative for preparations comprising 10 to 40 % (weight/volume) lipid or fluorocarbon emulsions.
- the present invention also contemplates emulsions comprising more than 40 % w/v and up to 125 % w/v of for instance hydrocarbon compounds; e.g. fluorinated and/or chlorinated derivatives thereof. With such emulsions the loading capacity of the liquid preparation may be well above the above given limits.
- the emulsions as such impact the efficacy of the xenon in the liquid preparation. Thus, for certain indications the required xenon concentration may be drastically lower.
- the preparation according to the invention can thus be combined with any known inhalation anaesthetic, i.e. an i.v. administration is accompanied by inhalation anaesthesia.
- any known inhalation anaesthetic i.e. an i.v. administration is accompanied by inhalation anaesthesia.
- the concentration or amount of inhalation anaesthetic used can be reduced.
- Another pharmacologically active agent in the preparation in addition to the inert gas.
- This can be an intravenous sedative or anaesthetic, for example.
- this agent is water-soluble or fat-soluble, it is then present in the aqueous phase or the lipid phase together with the xenon. 2
- 6-Diisopropylphenol which is an effective anaesthetic (for example 1.5 - 20 mg/ml) , is found to be particularly suitable for this purpose.
- fatty emulsion according to the invention can contain 2.5 - 20 mg of 2 , 6-diisopropylphenol, i.e. for example 2.5, 5.0, 7.5, 10, 15 or 20 mg, in addition to the xenon.
- the substance with an anaesthetic, analgesic or sedative action which is present together with the xenon can be another anaesthetic, an analgesic, a muscle relaxant or a sedative.
- suitable anaesthetics are barbiturates (barbital, phenobarbital, pentobarbital , secobarbital , hexobarbital and thiopental, inter alia) in general, and opioids.
- Known analgesics are, inter alia, compounds of the morphine type, e.g.
- anthranilic acid derivatives flufenamic acid, mefena ic acid
- acrylic acid derivatives diclofenac, tolmetin, zomepirac
- arylpropionic acid derivatives ibuprofen, naproxen, phenoprofen, ketoprofen
- indoleacetic or indenacetic acid derivatives indometacin, sulindac
- a preparation according to the invention can consequently serve several purposes: a) intravenous induction of anaesthesia (optionally with 2 , 6-diisopropylphenol or etomidate as a supporting component) ; b) supplementary intravenous administration in parallel with inhalation anaesthesia with xenon or another gas (e.g. laughing gas or desflurane) , it being possible considerably to reduce the amount of gas to be used overall; c) maintenance of anaesthesia over a prolonged period, the inert gas-containing preparation optionally being administered only as a supplement together with
- anaesthesia as the field of use.
- anaesthesia here includes both the induction and the maintenance of anaesthesia.
- the preparations according to the invention also have a pain eliminating action, which can become significant in conjunction with anaesthesia.
- the elimination of pain for example acute and chronic pain therapy, also comes to the fore, a degree of additional subanaesthetic or sedative action often being desirable.
- Intravenous administration in a subanaesthetic dose over a long period of time (1 h to several days) effects an increased pain inhibiting action.
- One particular field of use of a preparation according to the invention as an anaesthetic is emergency medicine.
- the invention can thus be understood as a liquid or gel-like preparation containing the inert gas in dissolved or dispersed form.
- the liquid or gel-like preparation according to the invention is characterized in that it contains the gas with the pharmacological action dissolved in a finely divided, separate phase.
- this separate phase is the disperse phase of a dispersion or emulsion.
- the separate phase containing the gas can also be the continuous phase.
- the preparations according to the invention are generally composed in such a way that the disperse phase as such has the property of dissolving the gas.
- a series of perfluorocarbon emulsions were prepared or purchased and loaded with xenon. The activity of the preparations was verified on an animal model (rabbit) . All the emulsions were used in the same way as the Intralipid preparations described above, i.e. the experimental animal was quickly anaesthetized by an injection in the ear (about 1 ml) .
- Each of the emulsions was placed in a beaker and loaded by having the xenon gas passed through it.
- perfluorocarbon compounds perfluorohexyloctane (1) , perfluorodecalin (2) , per- flubron (C 8 F 17 ) (3) .
- said compound (I-IV) is liquid or gaseous at room temperature (20°C) and has an oil/water partition coefficient (in n-octanol; 20°C) of about 20.
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-1999-7008165A KR100504287B1 (en) | 1997-03-10 | 1998-03-06 | Medicinal preparation containing a lipophilic inert gas |
PL98335444A PL189841B1 (en) | 1997-03-10 | 1998-03-06 | Lypophilic inert gas containing medical preparation |
AT98913672T ATE207754T1 (en) | 1997-03-10 | 1998-03-06 | MEDICAL PREPARATION CONTAINING A LIPOPHILIC NOBLE GAS |
SI9830049T SI0966291T1 (en) | 1997-03-10 | 1998-03-06 | Medicinal preparation containing a lipophilic inert gas |
DK98913672T DK0966291T3 (en) | 1997-03-10 | 1998-03-06 | Medical preparation containing a lipophilic noble gas |
CA002283227A CA2283227A1 (en) | 1997-03-10 | 1998-03-06 | Medicinal preparation containing a lipophilic inert gas |
EEP199900399A EE03807B1 (en) | 1997-03-10 | 1998-03-06 | A medicinal preparation containing lipophilic inert gas |
IL13155798A IL131557A0 (en) | 1997-03-10 | 1998-03-06 | Medical preparation containing a lipophilic inert gas |
BR9808227-2A BR9808227A (en) | 1997-03-10 | 1998-03-06 | Medicinal preparation containing lipophilic inert gas |
HU0001510A HU224985B1 (en) | 1997-03-10 | 1998-03-06 | Medicinal preparation containing a lipophilic inert gas |
APAP/P/1999/001630A AP1162A (en) | 1997-03-10 | 1998-03-06 | Medical preparation containing a lipophilic inert gas. |
NZ337534A NZ337534A (en) | 1997-03-10 | 1998-03-06 | Liquid emulsion containing a lipophilic inert gas such as xenon useful as an anaesthetic, analgesic or muscle relaxant |
AU68286/98A AU738946C (en) | 1997-03-10 | 1998-03-06 | Medicinal preparation containing a lipophilic inert gas |
EP98913672A EP0966291B1 (en) | 1997-03-10 | 1998-03-06 | Medicinal preparation containing a lipophilic inert gas |
SK1187-99A SK284249B6 (en) | 1997-03-10 | 1998-03-06 | Medicinal preparation containing a lipophilic inert gas |
DE69802268T DE69802268T2 (en) | 1997-03-10 | 1998-03-06 | MEDICAL PREPARATION CONTAINING A LIPOPHILIC EDELGAS |
UA99105498A UA64744C2 (en) | 1997-03-10 | 1998-06-03 | Medicinal preparation containing lipophilic inert gas |
NO994091A NO994091L (en) | 1997-03-10 | 1999-08-24 | Medical preparation containing a lipophilic inert gas |
HK00107595A HK1028335A1 (en) | 1997-03-10 | 2000-11-27 | Medicinal preparation containing a lipophilic inert gas |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19709704.9 | 1997-03-10 | ||
DE19709704A DE19709704C2 (en) | 1997-03-10 | 1997-03-10 | Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia |
EP97113757.5 | 1997-08-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998040083A1 true WO1998040083A1 (en) | 1998-09-17 |
Family
ID=7822782
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/001304 WO1998040083A1 (en) | 1997-03-10 | 1998-03-06 | Medicinal preparation containing a lipophilic inert gas |
PCT/EP1998/001305 WO1998040084A1 (en) | 1997-03-10 | 1998-03-06 | Device for controlled anaesthesia, analgesia and/or sedation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/001305 WO1998040084A1 (en) | 1997-03-10 | 1998-03-06 | Device for controlled anaesthesia, analgesia and/or sedation |
Country Status (33)
Country | Link |
---|---|
US (3) | US6328708B1 (en) |
EP (3) | EP0864328B1 (en) |
JP (1) | JPH10251142A (en) |
KR (2) | KR100504287B1 (en) |
CN (1) | CN1104901C (en) |
AP (1) | AP1162A (en) |
AT (3) | ATE198047T1 (en) |
AU (1) | AU738946C (en) |
BG (1) | BG64583B1 (en) |
BR (1) | BR9808227A (en) |
CA (1) | CA2283227A1 (en) |
CZ (1) | CZ292767B6 (en) |
DE (4) | DE19709704C2 (en) |
DK (2) | DK0864329T3 (en) |
EE (1) | EE03807B1 (en) |
ES (2) | ES2152608T3 (en) |
GR (1) | GR3035553T3 (en) |
HK (1) | HK1028335A1 (en) |
HU (1) | HU224985B1 (en) |
ID (1) | ID23151A (en) |
IL (1) | IL131557A (en) |
NO (1) | NO994091L (en) |
NZ (1) | NZ337534A (en) |
OA (1) | OA11156A (en) |
PL (1) | PL189841B1 (en) |
PT (2) | PT864329E (en) |
RU (1) | RU2204397C2 (en) |
SI (1) | SI0966291T1 (en) |
SK (1) | SK284249B6 (en) |
TR (1) | TR199902205T2 (en) |
TW (2) | TWI241914B (en) |
WO (2) | WO1998040083A1 (en) |
ZA (2) | ZA981953B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU757361B2 (en) * | 1999-03-11 | 2003-02-20 | Imperial Innovations Limited | Use of xenon for treating neurointoxications |
US6562855B1 (en) | 1999-06-11 | 2003-05-13 | Nicholas Peter Franks | Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist |
US6653354B2 (en) | 1999-07-29 | 2003-11-25 | Protexeon Limited | NMDA antagonist comprising xenon |
WO2003105872A1 (en) * | 2002-06-12 | 2003-12-24 | Messer Griesheim Gmbh | Anti-spasmodic comprising xenon |
EP1570852A2 (en) * | 2000-09-14 | 2005-09-07 | Air Liquide Deutschland GmbH | Xenon for use as drug |
US7235264B2 (en) | 2002-06-12 | 2007-06-26 | Air Liquide Deutschland Gmbh | Cerebral protection with a gas comprising xenon |
KR100881241B1 (en) * | 2000-09-15 | 2009-02-05 | 백스터 인터내셔널 인코포레이티드 | Container for inhalation anesthetic |
US9278048B2 (en) | 2009-05-06 | 2016-03-08 | Baxter International, Inc. | Pharmaceutical product and method of use |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19709704C2 (en) * | 1997-03-10 | 1999-11-04 | Michael Georgieff | Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia |
DE69937558T2 (en) * | 1998-06-03 | 2008-03-06 | Scott Laboratories, Inc., Lubbock | APPARATUS FOR AFFECTING PAIN IN AWARENESS AND FEARING STATE IN CONNECTION WITH MEDICAL AND SURGICAL PROCEDURES |
DE19833014A1 (en) * | 1998-07-23 | 2000-01-27 | Messer Griesheim Gmbh | Injectable anesthetic comprising noble gas(es) in gaseous form, also showing analgesic, sedative, antiinflammatory and muscle relaxant actions |
EP1105096B1 (en) * | 1998-08-19 | 2003-10-29 | Skyepharma Canada Inc. | Injectable aqueous dispersions of propofol |
DE19851604A1 (en) * | 1998-11-09 | 2000-05-11 | Messer Griesheim Gmbh | Injection anesthetic with a hydrophilic phase |
DE19851605A1 (en) * | 1998-11-09 | 2000-05-11 | Messer Griesheim Gmbh | Injection anesthetic containing microparticles |
DE19852472A1 (en) * | 1998-11-13 | 2000-05-25 | Messer Griesheim Gmbh | Analysis of liquids loaded with gases |
WO2001005409A1 (en) * | 1999-07-19 | 2001-01-25 | Michael Georgieff | Novel spinal and epidural anaesthetic |
GB9917822D0 (en) * | 1999-07-29 | 1999-09-29 | Imperial College | Nmda antagonist |
NZ518740A (en) | 1999-11-08 | 2004-04-30 | Univ Florida | Marker detection method and apparatus to monitor drug compliance |
US20020177232A1 (en) * | 2001-05-23 | 2002-11-28 | Melker Richard J. | Method and apparatus for detecting illicit substances |
US20050233459A1 (en) * | 2003-11-26 | 2005-10-20 | Melker Richard J | Marker detection method and apparatus to monitor drug compliance |
US20050037374A1 (en) * | 1999-11-08 | 2005-02-17 | Melker Richard J. | Combined nanotechnology and sensor technologies for simultaneous diagnosis and treatment |
US6623765B1 (en) * | 2000-08-01 | 2003-09-23 | University Of Florida, Research Foundation, Incorporated | Microemulsion and micelle systems for solubilizing drugs |
FR2812545B1 (en) * | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | INHALABLE DRUG AEROSOL FOR TREATMENT OR PREVENTION OF SWEETNESS |
US7104963B2 (en) * | 2002-01-22 | 2006-09-12 | University Of Florida Research Foundation, Inc. | Method and apparatus for monitoring intravenous (IV) drug concentration using exhaled breath |
US6981947B2 (en) * | 2002-01-22 | 2006-01-03 | University Of Florida Research Foundation, Inc. | Method and apparatus for monitoring respiratory gases during anesthesia |
WO2002045721A1 (en) * | 2000-12-04 | 2002-06-13 | Uws Ventures Limited | Noble gas complexes |
US7052854B2 (en) * | 2001-05-23 | 2006-05-30 | University Of Florida Research Foundation, Inc. | Application of nanotechnology and sensor technologies for ex-vivo diagnostics |
EP1393069A1 (en) * | 2001-05-24 | 2004-03-03 | The University Of Florida | Method and apparatus for detecting environmental smoke exposure |
DE10141650C1 (en) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate |
MXPA04004246A (en) * | 2001-11-01 | 2004-09-10 | Scott Lab Inc | User interface for sedation and analgesia delivery systems and methods. |
US20070167853A1 (en) * | 2002-01-22 | 2007-07-19 | Melker Richard J | System and method for monitoring health using exhaled breath |
DE10205056A1 (en) * | 2002-02-07 | 2003-08-14 | Hartwin Hobler | Method and apparatus for mixing gaseous or sparingly soluble active materials with other fluids, e.g. directly into blood stream, comprises feeding them in controlled doses into fluid using pressure pulses |
GB0209998D0 (en) * | 2002-05-01 | 2002-06-12 | Protexeon Ltd | Use |
MXPA04011423A (en) * | 2002-05-16 | 2005-02-17 | Scott Laborotories Inc | Kits of medical supplies for sedation and analgesia. |
US20040022842A1 (en) * | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
CN1665542A (en) * | 2002-07-05 | 2005-09-07 | 梅瑟·格里斯海姆有限公司 | Adjuvant containing xenon |
GB0218153D0 (en) * | 2002-08-05 | 2002-09-11 | Ic Innovations Ltd | An analgesic agent for newborn or retal subjects |
AU2003275460A1 (en) * | 2002-10-03 | 2004-04-23 | Scott Laboratories, Inc. | Systems and methods for providing trend analysis in a sedation and analgesia system |
US20060160134A1 (en) * | 2002-10-21 | 2006-07-20 | Melker Richard J | Novel application of biosensors for diagnosis and treatment of disease |
WO2004052337A2 (en) * | 2002-12-06 | 2004-06-24 | Michael Georgieff | Nasal pharmaceutical preparation containing an active lipophilic liquid or gaseous ingredient |
EP1610681B1 (en) * | 2003-01-23 | 2011-10-05 | University of Florida Research Foundation, Incorporated | Method and apparatus for monitoring intravenous (iv) drug concentration using exhaled breath |
US7390508B2 (en) * | 2003-10-10 | 2008-06-24 | Protexeon Limited | Use of xenon with hypothermia for treating neonatal asphyxia |
WO2005039600A2 (en) * | 2003-10-21 | 2005-05-06 | Aga Ab | Use of xenon for the prevention of programmed cell death |
US20050191757A1 (en) * | 2004-01-20 | 2005-09-01 | Melker Richard J. | Method and apparatus for detecting humans and human remains |
US20060062734A1 (en) * | 2004-09-20 | 2006-03-23 | Melker Richard J | Methods and systems for preventing diversion of prescription drugs |
JP2006248978A (en) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
US20060257883A1 (en) * | 2005-05-10 | 2006-11-16 | Bjoraker David G | Detection and measurement of hematological parameters characterizing cellular blood components |
US7914460B2 (en) | 2006-08-15 | 2011-03-29 | University Of Florida Research Foundation, Inc. | Condensate glucose analyzer |
ES2765007T3 (en) | 2008-01-22 | 2020-06-05 | Univ Texas | Volatile anesthetic compositions and methods of use |
AU2014277860A1 (en) * | 2008-01-22 | 2015-01-22 | Board Of Regents, The University Of Texas System | Volatile anesthetic compositions and methods of use |
WO2010033439A2 (en) * | 2008-09-17 | 2010-03-25 | The Brigham And Women's Hospital, Inc. | Anesthesia simulator and controller for closed-loop anesthesia |
AU2010245932B2 (en) | 2009-05-05 | 2015-08-06 | Board Of Regents, The University Of Texas System | Novel formulations of volatile anesthetics and methods of use for reducing inflammation |
US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
CN101961051A (en) * | 2010-09-08 | 2011-02-02 | 营口艾特科技有限公司 | Liquid containing xenon and preparation method thereof |
CN101940538B (en) * | 2010-09-08 | 2012-07-04 | 营口艾特科技有限公司 | Xenon-containing cosmetics and preparation method thereof |
CN101928636B (en) * | 2010-09-08 | 2012-11-14 | 营口艾特科技有限公司 | Xenon-containing grease-like liquid and preparation method thereof |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
PL2661280T3 (en) * | 2011-01-04 | 2019-05-31 | Novaliq Gmbh | O/w-emulsions comprising semifluorinated alkanes |
DK2714010T3 (en) | 2011-05-25 | 2017-06-12 | Novaliq Gmbh | TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORED ALKANES |
RU2475249C1 (en) * | 2011-10-05 | 2013-02-20 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН | Agent for external therapy of chronic recurrent inflammatory dermatopathies |
AU2013211645B2 (en) | 2012-01-23 | 2017-06-15 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
DE102012203897B4 (en) | 2012-03-13 | 2014-11-27 | Kist Europe Forschungsgesellschaft Mbh | Apparatus for performing anesthesia or analgesic sedation and method for operating an apparatus for performing anesthesia or analgesic sedation |
CN103565745A (en) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学系统董事会 | Neuroprotective liposome compositions and methods for treatment of stroke |
CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
CA3142049C (en) | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
AU2014233018A1 (en) * | 2013-03-15 | 2015-10-01 | The Board Of Regents Of The University Of Texas System | Liquids rich in noble gas and methods of their preparation and use |
KR101545706B1 (en) * | 2013-05-10 | 2015-08-26 | 주식회사 아미팜 | Composition comprising phosphatidylcholine for lipolysis and manufacturing method thereof |
CN105555311B (en) | 2013-07-23 | 2021-10-08 | 诺瓦利克有限责任公司 | Stabilized antibody compositions |
US20150328073A1 (en) * | 2014-05-19 | 2015-11-19 | Joseph Gerard Archer | Hyperbaric Social Establishment or Residence |
US10499838B2 (en) * | 2015-04-24 | 2019-12-10 | Drexel University | Non-invasive brain water monitoring device for cerebral edema and cerebral autoregulation monitoring system and method |
ES2803248T3 (en) | 2015-09-30 | 2021-01-25 | Novaliq Gmbh | 2-perfluorohexyl octane for ophthalmic administration |
CN110403923B (en) | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | Semifluorinated compounds and compositions thereof |
PT3442480T (en) | 2016-06-23 | 2019-12-23 | Novaliq Gmbh | Topical administration method |
US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
AU2018253944B2 (en) | 2017-04-21 | 2022-09-15 | Dermaliq Therapeutics, Inc. | Iodine compositions |
CN110650734A (en) | 2017-05-12 | 2020-01-03 | 诺瓦利克有限责任公司 | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of conditions associated with contact lenses |
MX2020003534A (en) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases. |
WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | Ophthalmic compositions comprising f6h8 |
AU2019228119A1 (en) | 2018-03-02 | 2020-09-10 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
WO2020074697A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
CN113811950A (en) * | 2018-12-14 | 2021-12-17 | 派尔疗法股份有限公司 | Digital therapeutic assembly for optimizing the induction of buprenorphine-containing products |
EP3839959A1 (en) * | 2019-12-19 | 2021-06-23 | Koninklijke Philips N.V. | Transdermal sedative release control in autonomous imaging |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1667926A1 (en) * | 1967-01-09 | 1971-11-04 | Union Carbide Corp | Process for the production of salt solutions containing radioactive gases |
WO1985000011A1 (en) * | 1983-06-17 | 1985-01-03 | Univ Miami | Microdroplets of water-insoluble drugs |
DE3940389A1 (en) * | 1989-12-06 | 1991-06-13 | Abolghassem Prof Dr M Pakdaman | Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases |
DE4100782A1 (en) * | 1991-01-12 | 1992-07-16 | Patentverwertung Dr J Haensler | Aq. ozone preparations for ozone therapy and microbicidal use - contain dissolved ozone and are prepd. by bubbling an oxygen@-ozone mixt. through aq. soln. |
EP0523315A1 (en) * | 1991-07-16 | 1993-01-20 | Praxair Technology, Inc. | Gas mixture for anesthesia consisting of xenon, oxygen and helium |
WO1995027438A1 (en) * | 1994-04-08 | 1995-10-19 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1472793A (en) * | 1974-03-28 | 1977-05-04 | Ici Ltd | Pharmaceutical compositions |
GR64915B (en) * | 1978-09-14 | 1980-06-09 | Janssen Pharmaceutica Nv | Improved etomidate-containing compositions |
US4725442A (en) * | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
US5140981A (en) | 1986-11-24 | 1992-08-25 | Picker International, Inc. | End-tidal gas detection |
SE8700977D0 (en) * | 1987-03-09 | 1987-03-09 | Olof Werner | UNIT WHICH SEPARATELY SEPARATES THE GAS CONTENT IN THE DRIVE CIRCUIT AND THE RECEIVER CIRCUIT BUT ONLY ALLOWS GAS PIPE IN THE BAD DIRECTIONS (OPEN SEPARATION) |
US4781698A (en) * | 1987-04-09 | 1988-11-01 | Parren Mark L | Selectable drop size infusion metering device |
DE3712598A1 (en) * | 1987-04-14 | 1988-10-27 | Siemens Ag | INHALATION ANESTHESIS DEVICE |
DE3828905A1 (en) * | 1988-08-23 | 1990-03-15 | Schering Ag | MEDIALLY COMPOSED OF CAVITATE OR CLATHRATE MAKING HOST / GUEST COMPLEX AS A CONTRAST |
US5088499A (en) | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5334381A (en) | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5320093A (en) | 1990-12-21 | 1994-06-14 | Brigham And Women's Hospital | Rapid anesthesia emergence system using closed-loop PCO2 control |
DE4132677C2 (en) * | 1991-10-01 | 1995-08-24 | Braun Melsungen Ag | Liposomes containing volatile inhalation anesthetics, their preparation and use |
DE4411533C1 (en) * | 1994-04-02 | 1995-04-06 | Draegerwerk Ag | Anaesthesia apparatus |
DE4432378A1 (en) * | 1994-09-12 | 1996-03-14 | Bayer Ag | Injectable liposomal drug preparations |
US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US5780010A (en) | 1995-06-08 | 1998-07-14 | Barnes-Jewish Hospital | Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system |
US5807321A (en) * | 1995-11-28 | 1998-09-15 | Merit Medical | System for electronically monitoring the delivery of contrast media |
SE9601348D0 (en) * | 1996-04-10 | 1996-04-10 | Pharmacia Ab | Improved containers for parenteral fluids |
SE9601719D0 (en) * | 1996-05-06 | 1996-05-06 | Siemens Elema Ab | Dosage for supply of additive gas or liquid to respiratory gas in anesthesia or ventilator |
DE19709704C2 (en) * | 1997-03-10 | 1999-11-04 | Michael Georgieff | Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia |
-
1997
- 1997-03-10 DE DE19709704A patent/DE19709704C2/en not_active Expired - Fee Related
- 1997-08-08 ES ES97113757T patent/ES2152608T3/en not_active Expired - Lifetime
- 1997-08-08 EP EP97113756A patent/EP0864328B1/en not_active Expired - Lifetime
- 1997-08-08 DK DK97113757T patent/DK0864329T3/en active
- 1997-08-08 EP EP97113757A patent/EP0864329B1/en not_active Expired - Lifetime
- 1997-08-08 AT AT97113757T patent/ATE198047T1/en not_active IP Right Cessation
- 1997-08-08 DE DE59702760T patent/DE59702760D1/en not_active Expired - Fee Related
- 1997-08-08 PT PT97113757T patent/PT864329E/en unknown
- 1997-08-08 DE DE59709351T patent/DE59709351D1/en not_active Expired - Fee Related
- 1997-08-08 AT AT97113756T patent/ATE232735T1/en not_active IP Right Cessation
-
1998
- 1998-02-24 TW TW087102607A patent/TWI241914B/en active
- 1998-02-24 TW TW087102606A patent/TW396040B/en active
- 1998-03-06 HU HU0001510A patent/HU224985B1/en not_active IP Right Cessation
- 1998-03-06 WO PCT/EP1998/001304 patent/WO1998040083A1/en active IP Right Grant
- 1998-03-06 EE EEP199900399A patent/EE03807B1/en not_active IP Right Cessation
- 1998-03-06 DK DK98913672T patent/DK0966291T3/en active
- 1998-03-06 SI SI9830049T patent/SI0966291T1/en unknown
- 1998-03-06 NZ NZ337534A patent/NZ337534A/en unknown
- 1998-03-06 PL PL98335444A patent/PL189841B1/en not_active IP Right Cessation
- 1998-03-06 AU AU68286/98A patent/AU738946C/en not_active Ceased
- 1998-03-06 RU RU99121178/14A patent/RU2204397C2/en not_active IP Right Cessation
- 1998-03-06 SK SK1187-99A patent/SK284249B6/en unknown
- 1998-03-06 ES ES98913672T patent/ES2162437T3/en not_active Expired - Lifetime
- 1998-03-06 BR BR9808227-2A patent/BR9808227A/en not_active Application Discontinuation
- 1998-03-06 KR KR10-1999-7008165A patent/KR100504287B1/en not_active IP Right Cessation
- 1998-03-06 WO PCT/EP1998/001305 patent/WO1998040084A1/en not_active Application Discontinuation
- 1998-03-06 TR TR1999/02205T patent/TR199902205T2/en unknown
- 1998-03-06 AT AT98913672T patent/ATE207754T1/en not_active IP Right Cessation
- 1998-03-06 CZ CZ19993173A patent/CZ292767B6/en not_active IP Right Cessation
- 1998-03-06 CN CN98804792A patent/CN1104901C/en not_active Expired - Fee Related
- 1998-03-06 PT PT98913672T patent/PT966291E/en unknown
- 1998-03-06 AP APAP/P/1999/001630A patent/AP1162A/en active
- 1998-03-06 EP EP98913672A patent/EP0966291B1/en not_active Expired - Lifetime
- 1998-03-06 KR KR1019997008206A patent/KR20000076117A/en not_active Application Discontinuation
- 1998-03-06 CA CA002283227A patent/CA2283227A1/en not_active Abandoned
- 1998-03-06 ID IDW990990A patent/ID23151A/en unknown
- 1998-03-06 DE DE69802268T patent/DE69802268T2/en not_active Expired - Fee Related
- 1998-03-09 ZA ZA9801953A patent/ZA981953B/en unknown
- 1998-03-09 ZA ZA9801958A patent/ZA981958B/en unknown
- 1998-03-10 US US09/037,793 patent/US6328708B1/en not_active Expired - Fee Related
- 1998-03-10 US US09/037,523 patent/US6197323B1/en not_active Expired - Fee Related
- 1998-03-10 JP JP10076604A patent/JPH10251142A/en active Pending
-
1999
- 1999-03-06 IL IL13155799A patent/IL131557A/en not_active IP Right Cessation
- 1999-08-24 NO NO994091A patent/NO994091L/en unknown
- 1999-09-02 BG BG103712A patent/BG64583B1/en unknown
- 1999-09-07 OA OA9900203A patent/OA11156A/en unknown
-
2000
- 2000-11-27 HK HK00107595A patent/HK1028335A1/en not_active IP Right Cessation
-
2001
- 2001-03-09 GR GR20010400394T patent/GR3035553T3/en not_active IP Right Cessation
- 2001-09-17 US US09/953,185 patent/US6511453B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1667926A1 (en) * | 1967-01-09 | 1971-11-04 | Union Carbide Corp | Process for the production of salt solutions containing radioactive gases |
WO1985000011A1 (en) * | 1983-06-17 | 1985-01-03 | Univ Miami | Microdroplets of water-insoluble drugs |
DE3940389A1 (en) * | 1989-12-06 | 1991-06-13 | Abolghassem Prof Dr M Pakdaman | Therapeutical compsn. comprising gas, e.g. oxygen dissolved in liq. - for immuno-stimulation in cancer therapy, reviving accident victims and improving oxygen transport in vascular coronary diseases |
DE4100782A1 (en) * | 1991-01-12 | 1992-07-16 | Patentverwertung Dr J Haensler | Aq. ozone preparations for ozone therapy and microbicidal use - contain dissolved ozone and are prepd. by bubbling an oxygen@-ozone mixt. through aq. soln. |
EP0523315A1 (en) * | 1991-07-16 | 1993-01-20 | Praxair Technology, Inc. | Gas mixture for anesthesia consisting of xenon, oxygen and helium |
WO1995027438A1 (en) * | 1994-04-08 | 1995-10-19 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU757361B2 (en) * | 1999-03-11 | 2003-02-20 | Imperial Innovations Limited | Use of xenon for treating neurointoxications |
US6562855B1 (en) | 1999-06-11 | 2003-05-13 | Nicholas Peter Franks | Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist |
AU778671B2 (en) * | 1999-06-11 | 2004-12-16 | Protexeon Limited | Anaesthetic formulation comprising an NMDA-antagonist and an alpha-2 adrenergic agonist |
US6653354B2 (en) | 1999-07-29 | 2003-11-25 | Protexeon Limited | NMDA antagonist comprising xenon |
EP1570852A2 (en) * | 2000-09-14 | 2005-09-07 | Air Liquide Deutschland GmbH | Xenon for use as drug |
EP1570852A3 (en) * | 2000-09-14 | 2005-11-23 | Air Liquide Deutschland GmbH | Xenon for use as drug |
KR100881241B1 (en) * | 2000-09-15 | 2009-02-05 | 백스터 인터내셔널 인코포레이티드 | Container for inhalation anesthetic |
KR100901049B1 (en) * | 2000-09-15 | 2009-06-04 | 백스터 인터내셔널 인코포레이티드 | Container for inhalation anesthetic |
WO2003105872A1 (en) * | 2002-06-12 | 2003-12-24 | Messer Griesheim Gmbh | Anti-spasmodic comprising xenon |
US7235264B2 (en) | 2002-06-12 | 2007-06-26 | Air Liquide Deutschland Gmbh | Cerebral protection with a gas comprising xenon |
US9278048B2 (en) | 2009-05-06 | 2016-03-08 | Baxter International, Inc. | Pharmaceutical product and method of use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU738946C (en) | Medicinal preparation containing a lipophilic inert gas | |
EP0583358B1 (en) | Partial liquid breathing of fluorocarbons | |
IL167472A (en) | Use of halogenated volatile anesthetic in the manufacture of a formulation for use in the treatment of a patient having tissue that is subject to an ischemic event | |
AU719407B2 (en) | Device for controlled anaesthesia, analgesia and/or sedation | |
UA64744C2 (en) | Medicinal preparation containing lipophilic inert gas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98804792.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 131557 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 68286/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 337534 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 118799 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998913672 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-3173 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997008165 Country of ref document: KR Ref document number: 1999/02205 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2283227 Country of ref document: CA Ref document number: 2283227 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/008308 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1998913672 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-3173 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref document number: 1998539194 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997008165 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998913672 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 68286/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1999-3173 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997008165 Country of ref document: KR |